Inspira Technologies has expanded the usage of its blood sensor technology, HYLA, into a personalised blood lab test.
The test is designed to perform real-time blood work on the patient potentially detecting life-threatening conditions in a reduced period.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The business model of the technology seeks to streamline extracorporeal procedures by reducing the need for intermittent physical blood samples.
HYLA aims to simplify the process of blood testing in various medical settings, including emergency rooms, intensive care units, and operating theatres. It also has the potential to replace expensive equipment, eliminate the requirement for blood cartridges, and decrease reliance on central labs, thereby easing the workload for hospital staff.
Clinical evaluations of the technology are currently underway at Sheba Hospital, focusing on individuals undergoing open-heart surgeries.
These evaluations are part of the preparation for the company’s planned submission to the US Food and Drug Administration (FDA) for the first configuration of the HYLA next year.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataInspira Technologies CEO Dagi Ben-Noon said: “Our plans to use HYLA to perform blood work without the need to take physical blood samples is part of a broader business strategy.
“The core technologies of the INSPIRA ART are progressing, with the Company currently performing a clinical evaluation of the HYLA blood technology at Sheba hospital, with results expected to be revealed in the near future.”
Specialised in life support and respiratory treatment, Inspira has developed the Augmented Respiration Technology (INSPIRA ART).
This device is designed to rapidly stabilise oxygen saturation levels in patients with acute respiratory failure, offering an alternative to mechanical ventilators.
Equipped with the HYLA blood sensor, the INSPIRA ART aims to provide continuous monitoring and alert physicians to changes in a patient’s condition.
The INSPIRA ART100 system has already achieved 510(k) clearance from the FDA for use in cardiopulmonary bypass procedures and also obtained the Israeli Ministry of Health’s medical devices and accessories (AMAR) certification.
